Investment company to acquire ZimVie for approximately $730 million
ZimVie, a dental devices company, has announced it is set to be acquired by an affiliate of Archimed, a healthcare investment firm based in Lyon, France, for approximately $730 million. The deal, which was announced on July 21, 2025, is expected to close by the end of the year, subject to shareholder and regulatory approvals [1][2][3].
The acquisition will take ZimVie private, with shareholders receiving $19.00 per share, representing a significant premium of up to 99% over recent trading prices [1][2][3]. The deal values the company at around 19.6 times its EBITDA. ZimVie has a 40-day "go-shop" period, expiring August 29, 2025, during which it can seek alternative proposals [1][2].
Archimed's interest in ZimVie stems from its strategic intent to support the growth of innovative dental technologies. ZimVie, having been spun out from Zimmer Biomet in 2022, focuses on dental implant and biomaterial solutions following the sale of its spine business [2][3].
ZimVie's CEO, Vafa Jamali, highlighted that the deal provides strategic and financial support to expand access to ZimVie’s dental innovations globally [2][3]. Archimed, in turn, underscores ZimVie’s strong fundamentals and growth potential in the dental device sector as key drivers for the investment [3].
The deal, expected to close by late 2025, aims to accelerate ZimVie’s growth in dental technology through Archimed’s backing, while providing shareholder value through a significant premium [1][2][3]. Following the announcement, ZimVie's shares more than doubled to $18.76 at market close on Monday.
Medtech M&A activity is expected to increase after a slow spring, despite lingering uncertainty about tariffs [4]. This acquisition follows several actions to divest parts of ZimVie, with the company being spun out of orthopedics firm Zimmer Biomet in 2022 to house its spine and dental implant businesses [1][2][3].
[1] Bloomberg. (2025). ZimVie Agrees to Sell Itself to Archimed for $730 Million. [online] Available at: https://www.bloomberg.com/news/articles/2025-07-21/zimvie-agrees-to-sell-itself-to-archimed-for-730-million
[2] Reuters. (2025). ZimVie to be Acquired by Archimed in $730 Million Deal. [online] Available at: https://www.reuters.com/business/healthcare-pharmaceuticals/zimvie-to-be-acquired-by-archimed-in-730-million-deal-2025-07-21/
[3] GlobeNewswire. (2025). ZimVie Announces Definitive Merger Agreement to be Acquired by Archimed. [online] Available at: https://globenewswire.com/news-release/2025/07/21/2490507/0/en/ZimVie-Announces-Definitive-Merger-Agreement-to-be-Acquired-by-Archimed.html
[4] Medical Design & Outsourcing. (2025). Medtech M&A Expected to Increase Despite Tariff Uncertainty. [online] Available at: https://www.mdo-mag.com/articles/medtech-ma-expected-to-increase-despite-tariff-uncertainty-57160
- Archimed, a healthcare investment firm, plans to acquire dental devices company ZimVie for approximately $730 million, as announced on July 21, 2025.
- The acquisition will take ZimVie private, with shareholders receiving $19.00 per share, representing a significant premium over recent trading prices.
- The deal values the company at around 19.6 times its EBITDA and is expected to close by the end of the year, subject to shareholder and regulatory approvals.
- ZimVie's CEO, Vafa Jamali, believes the deal will provide strategic and financial support to expand ZimVie’s dental innovations globally.
- Archimed's interest in ZimVie stems from its strategic intent to support the growth of innovative dental technologies.
- Medtech M&A activity is expected to increase in the coming months, following this acquisition and despite lingering uncertainty about tariffs.
